First Time Loading...
G

Gemini Therapeutics Inc
NASDAQ:GMTX

Watchlist Manager
Gemini Therapeutics Inc
NASDAQ:GMTX
Watchlist
Price: 19.89 USD 47.33% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

GMTX's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. [ Read More ]

The intrinsic value of one GMTX stock under the Base Case scenario is 4.5 USD. Compared to the current market price of 19.89 USD, Gemini Therapeutics Inc is Overvalued by 77%.

Key Points:
GMTX Intrinsic Value
Base Case
4.5 USD
Overvaluation 77%
Intrinsic Value
Price
G
Worst Case
Base Case
Best Case

Valuation Backtest
Gemini Therapeutics Inc

Backtest GMTX Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling GMTX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Gemini Therapeutics Inc's business.

What risks and challenges
does Gemini Therapeutics Inc face in the near future?

Summarize the latest earnings report
of Gemini Therapeutics Inc.

Provide P/E
for Gemini Therapeutics Inc and its competitors.

Financials

Balance Sheet Decomposition
Gemini Therapeutics Inc

Current Assets 198.5m
Cash & Short-Term Investments 194.6m
Other Current Assets 3.9m
Non-Current Assets 1.7m
PP&E 1.6m
Other Non-Current Assets 116k
Current Liabilities 22.6m
Accounts Payable 16.2m
Accrued Liabilities 6.4m
Non-Current Liabilities 1m
Other Non-Current Liabilities 1m
Efficiency

Earnings Waterfall
Gemini Therapeutics Inc

Revenue
0 USD
Operating Expenses
-47.5m USD
Operating Income
-47.5m USD
Other Expenses
648k USD
Net Income
-46.8m USD

Free Cash Flow Analysis
Gemini Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

GMTX Profitability Score
Profitability Due Diligence

Gemini Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROIC
Exceptional ROIC
Negative Free Cash Flow
Negative Operating Income
50/100
Profitability
Score

Gemini Therapeutics Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.

GMTX Solvency Score
Solvency Due Diligence

Gemini Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

Gemini Therapeutics Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

GMTX Price Targets Summary
Gemini Therapeutics Inc

There are no price targets for GMTX.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

GMTX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

GMTX Price
Gemini Therapeutics Inc

1M 1M
-
6M 6M
-
1Y 1Y
-
3Y 3Y
-87%
5Y 5Y
-81%
10Y 10Y
-81%
Annual Price Range
19.89
52w Low
N/A
52w High
N/A
Price Metrics
Average Annual Return 9.9%
Standard Deviation of Annual Returns
N/A
Max Drawdown -93%
Shares Statistics
Market Capitalization 860.1m USD
Shares Outstanding 43 244 500
Percentage of Shares Shorted 6.51%

GMTX Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Gemini Therapeutics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

860.1m USD

Dividend Yield

0%

Description

Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. The company is headquartered in Cambridge, Massachusetts and currently employs 31 full-time employees. The company went IPO on 2020-08-12. The firm is principally focused on developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration (AMD). The firm's lead product candidate, GEM103, is a recombinant form of the human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. Its Pipeline of product candidate includes (adeno-associated virus) AAV-CFH, AAV-CFI, AAV-Ab, GEM104 and GEM307. Its AAV-CFH program is complementary to GEM103 program, as AAV-CFH to construct that express GEM103 continuously at a therapeutic level. Its pipeline is designed to develop treatments for genetically subpopulations of patients suffering from dry AMD and linked diseases. The firm do not own or operate manufacturing facilities for the production of clinical or commercial quantities of its product candidates.

Contact

MASSACHUSETTS
Cambridge
300 One Kendall Square, 3Rd Floor, Suite 4500
+16174014400.0
https://geminitherapeutics.com/

IPO

2020-08-12

Employees

31

Officers

Interim Pres & CEO and Exec. Chairperson
Dr. Georges Gemayel C.F.A., Ph.D.
Chief Bus. Officer, CFO, Principal Accounting & Principal Financial Officer
Mr. Brian Piekos
Advisor
Mr. Jason Patrick Meyenburg M.B.A., M.D.
VP of Fin. & Controller
Mr. Patrick Truesdell

See Also

Discover More
What is the Intrinsic Value of one GMTX stock?

The intrinsic value of one GMTX stock under the Base Case scenario is 4.5 USD.

Is GMTX stock undervalued or overvalued?

Compared to the current market price of 19.89 USD, Gemini Therapeutics Inc is Overvalued by 77%.